What to expect with Ranexa

Ranexa is a prescription medicine used to treat adults with angina that keeps coming back (chronic angina). Ranexa may be used with other medicines that are used for heart problems and blood pressure control.

Please see Important Safety Information about Ranexa.

The CARISA study was a 12-week clinical trial of about 800 patients with chronic angina. About a third of the patients took Ranexa (ranolazine) 1000 mg and their regular angina medicines. Another group of patients took their regular medicines without Ranexa. The average age of patients in the study was 64 years old. Over 75% of them were men.

The study showed that, compared to patients taking their regular angina medicines without Ranexa, patients taking Ranexa had1:

More time walking

Exercise time on a treadmill stress test went up by 24 seconds.

Fewer angina attacks

Angina attacks per week went down by more than 30% (from 3 to 2).

Less nitroglycerin use

Patients taking Ranexa used fewer nitroglycerin tablets per week. The number of tablets taken per week went down more than 30% (from 3 to 2).

Not all patients respond to Ranexa the same way. Men improved more than women in exercise time and in lowering the number of angina attacks per week. In the CARISA study, the most common side effects reported were constipation, dizziness, nausea, and weakness.


Who should not take Ranexa?

Do not take Ranexa if:

Please see additional Important Safety Information about Ranexa.

Learn more about Ranexa:


What are the possible side effects of Ranexa?

What else do I need to know about taking Ranexa?

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch, or call 1‐800‐FDA‐1088.

Please see full Prescribing Information including Patient Information for Ranexa (ranolazine).


  1. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-316.